MARKET

MTEM

MTEM

Molecular US
NASDAQ

Real-time Quotes | Nasdaq Last Sale

7.60
+0.95
+14.29%
After Hours: 7.76 +0.16 +2.11% 19:50 09/24 EDT
OPEN
6.95
PREV CLOSE
6.65
HIGH
7.85
LOW
6.78
VOLUME
1.48M
TURNOVER
--
52 WEEK HIGH
15.19
52 WEEK LOW
5.70
MARKET CAP
426.68M
P/E (TTM)
-4.1523
1D
5D
1M
3M
1Y
5Y
ZIVO Bioscience, Pieris Pharmaceuticals leads healthcare gainers; Kintara Therapeutics, Onconova Therapeutics among major losers
Gainers: ZIVO Bioscience (NASDAQ:ZIVO) +68%, Pieris Pharmaceuticals (NASDAQ:PIRS) +11%, Molecular Templates (NASDAQ:MTEM) +11%, Paratek Pharmaceuticals (NASDAQ:PRTK) +9%, Capricor Therapeutics (NASDAQ:CAPR) +4%. Losers: Kintara Therapeutics (NASDAQ:KTRA) -...
Seekingalpha · 1d ago
Molecular Templates Shares Rise Amid Higher Trading Volume
MT Newswires · 1d ago
Molecular Templates Inc. (MTEM) Moves 11.8% Higher: Will This Strength Last?
Zacks.com · 3d ago
Molecular Templates to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
AUSTIN, Texas, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary engineered toxin bodies (ETBs), ...
GlobeNewswire · 5d ago
The Daily Biotech Pulse: NRx Rises On COVID-19 Drug Collaboration, Amgen's Lung Cancer Drug Conditionally Approved In Canada, Coherus Data Readout
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 13)
Benzinga · 09/14 11:50
Molecular Templates Q2 EPS $(0.28) Up From $(0.68) YoY, Sales $15.10M Up From $6.91M YoY
Molecular Templates (NASDAQ:MTEM) reported quarterly losses of $(0.28) per share. This is a 58.82 percent increase over losses of $(0.68) per share from the same period last year. The company reported $15.10 million in
Benzinga · 08/12 21:13
BRIEF-Molecular Templates, Inc. Reports Second Quarter 2021 Financial Results
reuters.com · 08/12 20:53
-- Earnings Flash (MTEM) MOLECULAR TEMPLATES Reports Q2 Revenue $15.1M
MT Newswires · 08/12 16:32
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of MTEM. Analyze the recent business situations of Molecular US through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 9 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average MTEM stock price target is 13.43 with a high estimate of 18.00 and a low estimate of 8.00.
EPS
Institutional Holdings
Institutions: 128
Institutional Holdings: 36.96M
% Owned: 65.83%
Shares Outstanding: 56.14M
TypeInstitutionsShares
Increased
42
3.53M
New
8
315.32K
Decreased
19
2.21M
Sold Out
21
1.69M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.13%
Pharmaceuticals & Medical Research
-1.02%
Key Executives
Chairman/Director
Harold Selick
President/Chief Operating Officer
Jason Kim
Chief Executive Officer/Chief Scientific Officer/Director
Eric Poma
Chief Financial Officer/Senior Vice President - Finance/Chief Accounting Officer/Controller/Treasurer
Sean McLennan
Other
Roger Waltzman
Independent Director
David Hirsch
Independent Director
David Hoffmann
Independent Director
Kevin Lalande
Independent Director
Jonathan Lanfear
Independent Director
Scott Morenstein
Independent Director
Corazon Sanders
No Data
  • All
  • Financials
  • Insiders
More
About MTEM
Molecular Templates, Inc., formerly Threshold Pharmaceuticals, Inc., is a clinical-stage biotechnology company. The Company is engaged in the discovery and development of therapeutic and diagnostic agents that selectively target tumor cells for the treatment of patients living with cancer. The Company also focused on the discovery, development, and commercialization of immunotoxins called engineered toxin bodies (ETBs). The Company is developing two therapeutic product candidates based on hypoxia-activated prodrug technology: evofosfamide and tarloxotinib. The Company’s lead drug candidate MT-3724 is an is an immunotoxin that targets the CD20 cell surface antigen present in a variety of lymphomas and leukemias.

Webull offers kinds of Molecular Templates Inc stock information, including NASDAQ:MTEM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MTEM stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MTEM stock methods without spending real money on the virtual paper trading platform.